Fingolimod - Development of signal transduction inhibitors for the therapy of multiple sclerosis;Fingolimod - Entwicklung von signaltransduktionshemmern für die therapie der multiplen sklerose

Nervenheilkunde

Volumn 30, Issue 5, 2011, Pages 345-349

  Ocker, Matthias ^a   Tackenberg, B ^b   Strik, H ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Fingolimod; FTY720; Signal transduction inhibition; Sphingosine 1 phosphate; Sphingosinkinase 1

Indexed keywords

FINGOLIMOD;

CHEMICAL REACTION; DRUG EFFECT; MULTIPLE SCLEROSIS; REVIEW; SIGNAL TRANSDUCTION;

EID: 80052572939     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1627821     Document Type: Review

References (40)

1. Alemany R., Van Koppen C.J., Danneberg K., Ter Braak M., Meyer Zu Heringdorf D. Regulation and functional roles of sphingosine kinases. Naunyn Schmiedebergs Arch Pharmacol 2007; 374(5-6): 413-428 (Pubitemid 46215289)
2. Allende M.L., Dreier J.L., Mandala S., Proia R.L. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J Biol Chem 2004; 279(15): 15396-15401 (Pubitemid 38618938)
3. Allende M.L., Yamashita T., Proia R.L. G-proteincoupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood 2003; 102(10): 3665-3667 (Pubitemid 37409386)
4. Alvarez S.E., Milstien S., Spiegel S. Autocrine and paracrine roles of sphingosine-1-phosphate. Trends Endocrinol Metab 2007; 18(8): 300-307 (Pubitemid 47531961)
5. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 2007; 115(1): 84-105. (Pubitemid 46990553)
6. Brinkmann V. FTY720 (fingolimod) in Multiple Sclerosis: Therapeutic effects in the immune and the central nervous system. Br J Pharmacol 2009; 158(5): 1173-1182
7. Chae S.S., Proia R.L., Hla T. Constitutive expression of the S1P1 receptor in adult tissues. Prostaglandins Other Lipid Mediat 2004; 73(1-2): 141-150 (Pubitemid 38446477)
8. Chiba K., Yanagawa Y., Masubuchi Y., Kataoka H., Kawaguchi T., Ohtsuki M. et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 1998; 160(10): 5037-5044 (Pubitemid 28215340)
9. Cohen J.A., Barkhof F., Comi G., Hartung H.P., Khatri B.O., Montalban X. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362(5): 402-415
10. Comi G., O'Connor P., Montalban X., Antel J., Radue E.W., Karlsson G. et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 2010; 16(2): 197-207.
11. Compston A., Coles A. Multiple sclerosis. Lancet 2002; 359(9313): 1221-1231 (Pubitemid 34304266)
12. Dev K.K., Mullershausen F., Mattes H., Kuhn R.R., Bilbe G., Hoyer D. et al. Brain sphingosine-1-phosphate receptors: Implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther 2008; 117(1): 77-93. (Pubitemid 350192672)
13. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis - The plaque and its pathogenesis. N Engl J Med 2006; 354(9): 942-955
14. Fugger L., Friese M.A., Bell J.I. From genes to function: The next challenge to understanding multiple sclerosis. Nat Rev Immunol 2009; 9(6): 408-417
15. Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms underlying inflammation in neurodegeneration. Cell 2010; 140(6): 918-934
16. Haghikia A., Gold R. The impact of fingolimod (FTY720) in neuroimmunologic diseases: Mechanisms beyond immunomodulation. Am J Pathol 2004; 176(6): 2599-2601
17. Herr D.R., Chun J. Effects of LPA and S1P on the nervous system and implications for their involvement in disease. Curr Drug Targets 2007; 8(1): 155-167 (Pubitemid 46043906)
18. Hla T. Physiological and pathological actions of sphingosine 1-phosphate. Semin Cell Dev Biol 2004; 15(5): 513-520 (Pubitemid 38953947)
19. Holmoy T., Harbo H., Vartdal F., Spurkland A. Genetic and molecular approaches to the immunopathogenesis of multiple sclerosis: An update. Curr Mol Med 2009; 9(5): 591-611.
20. Honig S.M., Fu S., Mao X., Yopp A., Gunn M.D., Randolph G.J. et al. FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes. J Clin Invest 2003; 111(5): 627-637 (Pubitemid 36278581)
21. Jaillard C., Harrison S., Stankoff B., Aigrot M.S., Calver A.R., Duddy G. et al. Edg8/S1P5: An oligodendroglial receptor with dual function on process retraction and cell survival. J Neurosci 2005; 25(6): 1459-1469 (Pubitemid 40250722)
22. Kantarci O., Wingerchuk D. Epidemiology and natural history of multiple sclerosis: New insights. Curr Opin Neurol 2006; 19(3): 248-254 (Pubitemid 43804678)
23. Kappos L., Radue E.W., O'Connor P., Polman C., Hohlfeld R., Calabresi P. et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362(5): 387-401.
24. Kihara A., Igarashi Y. Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720. Biochim Biophys Acta 2008; 1781(9): 496-502.
25. Kluk M.J., Hla T. Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G-proteincoupled receptors. Biochim Biophys Acta 2002; 1582(1-3): 72-80. (Pubitemid 34634113)
26. Kuntz N.L., Chabas D., Weinstock-Guttman B., Chitnis T., Yeh E.A., Krupp L. et al. Treatment of multiple sclerosis in children and adolescents. Expert Opin Pharmacother 2010; 11(4): 505-520
27. Lassmann H., Bruck W., Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: Implications for diagnosis and therapy. Trends Mol Med 2001; 7(3): 115-121 (Pubitemid 32201673)
28. Mandala S., Hajdu R., Bergstrom J., Quackenbush E., Xie J., Milligan J. et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296(5566): 346-349 (Pubitemid 34303689)
29. Matloubian M., Lo C.G., Cinamon G., Lesneski M.J., Xu Y., Brinkmann V. et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427(6972): 355-360 (Pubitemid 38133663)
30. McVerry B.J., Garcia J.G. In vitro and in vivo modulation of vascular barrier integrity by sphingosine 1-phosphate: Mechanistic insights. Cell Signal 2005; 17(2): 131-139 (Pubitemid 39371042)
31. Mehling M., Brinkmann V., Antel J., Bar-Or A., Goebels N., Vedrine C. et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008; 71(16): 1261-1267
32. Meyer zu Heringdorf D., Jakobs K.H. Lysophospholipid receptors: Signalling, pharmacology and regulation by lysophospholipid metabolism. Biochim Biophys Acta 2007; 1768(4): 923-940 (Pubitemid 46452543)
33. Miron V.E., Ludwin S.K., Darlington P.J., Jarjour A.A., Soliven B., Kennedy T.E. et al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol 2010; 176(6): 2682-2694
34. Mizugishi K., Yamashita T., Olivera A., Miller G.F., Spiegel S., Proia R.L. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol 2005; 25(24): 11113-11121 (Pubitemid 41747151)
35. Nixon G.F. Sphingolipids in inflammation: Pathological implications and potential therapeutic targets. Br J Pharmacol 2009; 158(4): 982-993
36. Pappu R., Schwab S.R., Cornelissen I., Pereira J.P., Regard J.B., Xu Y., et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 2007; 316(5822): 295-298 (Pubitemid 46633109)
37. Spiegel S., Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2004; 4(5): 397-407.
38. van Meer G, Lisman Q. Sphingolipid transport: rafts and translocators. J Biol Chem 2002; 277(29): 25855-25858
39. Zemann B., Kinzel B., Muller M., Reuschel R., Mechtcheriakova D., Urtz N., et al. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 2006; 107(4): 1454-1458 (Pubitemid 43242381)
40. Zuvich R.L., McCauley J.L., Pericak-Vance M.A., Haines J.L. Genetics and pathogenesis of multiple sclerosis. Semin Immunol 2009; 21(6): 328-333